{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:30Z","timestamp":1761871470546,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clml.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:18:34Z","timestamp":1583497114000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-0190","authenticated-orcid":false,"given":"Ahmed A.","family":"Alnagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosaad M.","family":"EL Gammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naera","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Samra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.02.002_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc840","article-title":"Core-binding factors in haematopoiesis and leukaemia","volume":"2","author":"Speck","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2020.02.002_bib2","series-title":"World Health Organization Classification of Tumours","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2020.02.002_bib3","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.02.002_bib4","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Frohling","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib5","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib6","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.leukres.2011.06.003","article-title":"Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia","volume":"35","author":"Park","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.02.002_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.12131","article-title":"The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients","volume":"160","author":"Kok","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.02.002_bib9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ejh.13089","article-title":"Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-\/high-dose cytarabine","volume":"101","author":"Prabahran","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.02.002_bib13","first-page":"20","article-title":"Detection of KIT mutations in core binding factor acute myeloid leukemia","volume":"10","author":"Badr","year":"2018","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2020.02.002_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML study group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2013.186","article-title":"The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia","volume":"27","author":"Allen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.02.002_bib16","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1002\/cam4.1733","article-title":"Core-binding factor acute myeloid leukemia with t(8;21): risk factors and a novel scoring system (I-CBFit)","volume":"7","author":"Ustun","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2020.02.002_bib17","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1038\/bcj.2016.107","article-title":"Kinase-associated gene mutation pattern and clinical relevance in 205 patients with core binding factor leukemias","volume":"6","author":"Chen","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.02.002_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3324\/haematol.2012.078030","article-title":"Prognosis of patients with core binding factor acute myeloid leukemia after first relapse","volume":"98","author":"Kurosawa","year":"2013","journal-title":"Haematological"},{"key":"10.1016\/j.clml.2020.02.002_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ajh.23281","article-title":"A\u00a0genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia","volume":"87","author":"Huh","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.02.002_bib20","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21) AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.02.002_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/10428194.2011.603447","article-title":"Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis","volume":"53","author":"Parihar","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.02.002_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-012-1580-5","article-title":"KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1\/RUNX1T1 rearrangement","volume":"92","author":"Kim","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.02.002_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ajh.24000","article-title":"Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up","volume":"90","author":"Mosna","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.02.002_bib24","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clml.2017.09.017","article-title":"Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia","volume":"18","author":"Khan","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.02.002_bib25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1080\/10428190903085951","article-title":"Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome","volume":"50","author":"Markov\u00e1","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.02.002_bib26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.leukres.2014.09.017","article-title":"Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center","volume":"38","author":"Qin","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.02.002_bib27","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3892\/or.2013.2328","article-title":"Core binding factor acute myeloid leukemia and c-KIT mutations","volume":"29","author":"Riera","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2020.02.002_bib28","first-page":"1037","article-title":"Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia","volume":"34","author":"Jung","year":"2014","journal-title":"Anticancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:57Z","timestamp":1761870897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2152265020300677"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}